Cepheid: FDA filings under this applicant name

FDA lists 63 510(k) clearances under 2 spellings of the applicant name “Cepheid” (first 2006, latest 2026), plus 3 De Novo decisions, across 26 product codes in 2 review panels. Median 510(k) review time under this name: 88 days. Since 2017 the median was 91 days, against 118 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.

Caduvo groups this applicant name under Danaher (Beckman Coulter, Leica Biosystems, Radiometer, Cepheid), based on public ownership records.

510(k) clearances per year

YearClearancesMedian review days
20124116
2013180
20142100
20153128
2016486
20174169
2018591
2019387
20200—
20210—
20223209
20235160
2024323
2025658
2026878

Review time against the same product codes

Since 2017, 510(k)s cleared under the name Cepheid took a median 91 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 118 days.

Top product codes

Product codeDeviceSubmissions510(k) clearances
NQXSystem, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen1010
OCCRespiratory Virus Panel Nucleic Acid Assay System88
QOFMulti-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents77
NJRNucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test55
POCSystem, Nucleic Acid Amplification Test, Dna, Antimicrobial Resistance Marker, Direct Specimen33
PQAVaginitis And Bacterial Vaginosis Nucleic Acid Detection System33
LSLDna-Reagents, Neisseria22
NIJSystem, Test, Genotypic Detection, Resistant Markers, Enterococcus Species22
NPRTest, Factor Ii G20210a Mutations, Genomic Dna Pcr22
OQW2009 H1n1 Influenza Virus (Swine Origin), Nucleic Acid Or Antigen, Detection And Identification22

Plus 16 more product codes.

Review panels

Most recent Cepheid 510(k) clearances

510(k)DeviceProduct codeDecision dateReview days
K262971Xpert® Hemorrhagic Fever PanelQVR2026-10-3065
K263333Xpert Xpress CoV-2/Flu plusQOF2026-10-2230
K263120Xpert Xpress CoV-2/Flu plusQOF2026-10-0228
K261336Xpert Respiratory PanelQOF2026-09-25155
K261362Xpert Hemorrhagic FeverQVR2026-08-07102
K261867Xpert Carba-RPOC2026-07-0228
K253653Xpert Hemorrhagic Fever—2026-02-2092
K251721Xpert GI PanelPCH2026-01-16226
K250996Xpert Xpress CoV-2/Flu/RSV plusQOF2025-05-0130
K250995Xpert Xpress CoV-2/Flu/RSV plusQOF2025-05-0130

53 earlier clearances. See the full list in Caduvo.

PMA and De Novo decisions

NumberPathwayDeviceDecision date
DEN240016De NovoSimple Point-Of-Care Nucleic Acid-Based Hepatitis C Virus Ribonucleic Acid Test2024-06-27
DEN130032De NovoSystem, Nucleic Acid-Based, Mycobacterium Tuberculosis Complex, Resistance Marker, Direct Specimen2013-07-25
DEN070004De NovoAssay, Enterovirus Nucleic Acid2007-03-16

Recalls

19 product recalls in 15 recall events; 7 initiated in the last five years. Most recent: 2025-11-05.

Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.

Device clinical trials

An industry sponsor named Cepheid is the lead sponsor of 3 device studies on ClinicalTrials.gov (0 active or recruiting). Most recent:

Parent company SEC filings

DANAHER CORP /DE/ (DHR): EDGAR filings, CIK 313616. Caduvo groups Cepheid under Danaher (Beckman Coulter, Leica Biosystems, Radiometer, Cepheid); the parent's SEC registrant is entered by hand for the group, not matched by name.

FDA spellings included

FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:

Frequently asked questions

How many FDA 510(k) clearances are listed under Cepheid?

FDA lists 63 510(k) clearances under 2 spellings of the applicant name “Cepheid” (first 2006, latest 2026), plus 3 De Novo decisions, across 26 product codes in 2 review panels. Filings under other applicant names, such as subsidiaries, are not included.

How long has FDA taken to clear 510(k)s filed by Cepheid?

The median time from FDA receipt to decision across 510(k)s cleared under the name Cepheid is 88 days. Since 2017: 91 days, versus 118 days for all cleared 510(k)s in the same product codes.

Which FDA product codes appear under Cepheid?

The most frequent FDA product codes under this applicant name are NQX (System, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen, 10); OCC (Respiratory Virus Panel Nucleic Acid Assay System, 8); QOF (Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents, 7).

Next steps

Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.

All FDA device companies · FDA product code lookup